三阴乳腺癌的内科治疗进展_West China Medical Journal

Authors：

李永霞 ,  刘磊 , 李平 , 汪娟

Corresponding author：

刘磊, Email: lyx7215210@163.com

Keywords：

三阴乳腺癌; 内科治疗

DOI：

CNKI: 51-1356/R.20120115.1555.039

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

三阴乳腺癌是乳腺癌中一类影响乳腺癌预后的特殊类型，因其临床及病理特点的特殊性，导致三阴乳腺癌的治疗成为世界性的难题。近年来，研究者们对三阴乳腺癌的内科治疗进行了一系列的探索，加上三阴乳腺癌特殊靶点的发现以及靶向药物的发展，希望三阴乳腺癌通过内科治疗从而改善预后。现对其内科治疗进展进行综述。

Citation： 李永霞,刘磊,李平,汪娟. 三阴乳腺癌的内科治疗进展. West China Medical Journal, 2012, 27(1): 141-144. doi: CNKI: 51-1356/R.20120115.1555.039 Copy

1.	Conforti R, Bidard FC, Michiels S, et al. Discrepancy between triple negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 “triple negative” breast cancers[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S135.
2.	Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes[J]. Ann Oncol, 2008, 19(7): 1261-1265.
3.	Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281.
4.	周波, 谢菲, 王思源, 等. 紫杉类联合蒽环类的新辅助化疗方案治疗三阴乳腺癌的疗效及预后[J]. 中国癌症杂志, 2009, 19(2): 129-132.
5.	Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
6.	Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 203.
7.	Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
8.	Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER2 and topoiso-merase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat, 2008, 107(69): 214.
9.	Ellis P, Barrett-Lee P, Johnson L, et al. Sequential doce-taxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase Ⅲ, randomized controlled trial[J]. Lancet, 2009,.
10.	Königsberg R, Pfeiler G, Kurzawa R, et al. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients [J]. Cancer Invest, 2011, 29(2): 180-186.
11.	Kennedy CR, Feng Gao, Julie A. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer[J]. J Surg Res, 2010, 163(1): 52-57.
12.	Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol, 2010, 28(3): 375–379.
13.	Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple-negative breast cancer patients compared to non-triple negative patients[J]. Breast, 2010, 19(3): 246-248.
14.	Staudacher L, Cottu PH, Dieras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience[J]. Ann Oncol, 2011, 22(4): 848-856.
15.	吴立新, 黄玉霞, 方月兰, 等. 吉西他滨联合顺铂二线治疗晚期三阴乳腺癌的临床观察[J]. 安徽医药, 2011, 15(9): 1149-1150.
16.	O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial[J]. J Clin Oncol Meeting Abstracts, 2009, 27(18S): 3.
17.	Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer[J]. Anti-Cancer Drugs, 2007, 18(7): 835-837.
18.	Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract 1009)[J]. J Clin Oncol, 2008, 26(suppl 15): 43.
19.	O’Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatinwith or without cetuximab in patients with metastatic breast cancer (abstract 308)[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S32.
20.	Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and ef?cacy[J]. J Clin Oncol, 2009, 27(15S): 551.
21.	Anthony E, Dragun, MD, Jianmin Pan, et al. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study[J]. Am J Clin Oncol, 2011, 34(3): 231-237.
22.	Freedman GM, Anderson PR, Li Tianyu, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation[J]. Cancer, 2009, 115(5): 946-951.
23.	Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-4434.
24.	袁中玉, 王树森, 高岩, 等. 305例三阴乳腺癌患者的临床特征及预后因素分析[J]. 癌症, 2008, 27(6): 561-565.
25.	Rhee J, Oh S, Oh D, et al. Does triple-negative breast cancer (TNBC) have distinct clinicopathologic characteristics and prognostic signi?cance? [J]. J Clin Oncol, 2007, 25(18S): 21088.
26.	林坚, 胡梅, 齐彭炜, 等. 三阴乳腺癌的临床病理特征及预后[J]. 中国癌症杂志, 2010, 20(6): 462-465.
27.	Kowalski PJ, Rubin MA, Kleei CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases[J]. Breast Cancer Res, 2003, 5(6): 217-222.
28.	李治, 帅晓明, 黄韬. MMP-2、MMP-9在乳腺癌转移中作用的研究[J]. 华西医学, 2006, 21(1): 43-44.
29.	Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and in creased risk for recurrence in patients with triple-negative breast cancer[J]. Ann Oncol, 2008, 19(4): 669-674.
30.	Tischkowitz M, Brunet JS, Bgin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 134.
31.	(9676): 1681-1692.

1. 　Conforti R, Bidard FC, Michiels S, et al. Discrepancy between triple negative phenotype and basal-like tumor: an immunohistochemical analysis based on 150 “triple negative” breast cancers[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S135.
2. 　Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes[J]. Ann Oncol, 2008, 19(7): 1261-1265.
3. 　Liedtke C, Mazouni C, Hess K, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol, 2008, 26(8): 1275-1281.
4. 　周波, 谢菲, 王思源, 等. 紫杉类联合蒽环类的新辅助化疗方案治疗三阴乳腺癌的疗效及预后[J]. 中国癌症杂志, 2009, 19(2): 129-132.
5. 　Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
6. 　Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 203.
7. 　Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
8. 　Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER2 and topoiso-merase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Br Cancer Res Treat, 2008, 107(69): 214.
9. 　Ellis P, Barrett-Lee P, Johnson L, et al. Sequential doce-taxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase Ⅲ, randomized controlled trial[J]. Lancet, 2009,.
10. 　Königsberg R, Pfeiler G, Kurzawa R, et al. Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients [J]. Cancer Invest, 2011, 29(2): 180-186.
11. 　Kennedy CR, Feng Gao, Julie A. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer[J]. J Surg Res, 2010, 163(1): 52-57.
12. 　Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol, 2010, 28(3): 375–379.
13. 　Koshy N, Quispe D, Shi R, et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple-negative breast cancer patients compared to non-triple negative patients[J]. Breast, 2010, 19(3): 246-248.
14. 　Staudacher L, Cottu PH, Dieras V, et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience[J]. Ann Oncol, 2011, 22(4): 848-856.
15. 　吴立新, 黄玉霞, 方月兰, 等. 吉西他滨联合顺铂二线治疗晚期三阴乳腺癌的临床观察[J]. 安徽医药, 2011, 15(9): 1149-1150.
16. 　O’Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial[J]. J Clin Oncol Meeting Abstracts, 2009, 27(18S): 3.
17. 　Gholam D, Chebib A, Hauteville D, et al. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer[J]. Anti-Cancer Drugs, 2007, 18(7): 835-837.
18. 　Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract 1009)[J]. J Clin Oncol, 2008, 26(suppl 15): 43.
19. 　O’Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatinwith or without cetuximab in patients with metastatic breast cancer (abstract 308)[J]. Breast Cancer Res Treat, 2007, 106(Suppl 1): S32.
20. 　Ryan PD, Tung NM, Isakoff SJ, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and ef?cacy[J]. J Clin Oncol, 2009, 27(15S): 551.
21. 　Anthony E, Dragun, MD, Jianmin Pan, et al. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study[J]. Am J Clin Oncol, 2011, 34(3): 231-237.
22. 　Freedman GM, Anderson PR, Li Tianyu, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation[J]. Cancer, 2009, 115(5): 946-951.
23. 　Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-4434.
24. 　袁中玉, 王树森, 高岩, 等. 305例三阴乳腺癌患者的临床特征及预后因素分析[J]. 癌症, 2008, 27(6): 561-565.
25. 　Rhee J, Oh S, Oh D, et al. Does triple-negative breast cancer (TNBC) have distinct clinicopathologic characteristics and prognostic signi?cance? [J]. J Clin Oncol, 2007, 25(18S): 21088.
26. 　林坚, 胡梅, 齐彭炜, 等. 三阴乳腺癌的临床病理特征及预后[J]. 中国癌症杂志, 2010, 20(6): 462-465.
27. 　Kowalski PJ, Rubin MA, Kleei CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases[J]. Breast Cancer Res, 2003, 5(6): 217-222.
28. 　李治, 帅晓明, 黄韬. MMP-2、MMP-9在乳腺癌转移中作用的研究[J]. 华西医学, 2006, 21(1): 43-44.
29. 　Eralp Y, Derin D, Ozluk Y, et al. MAPK overexpression is associated with anthracycline resistance and in creased risk for recurrence in patients with triple-negative breast cancer[J]. Ann Oncol, 2008, 19(4): 669-674.
30. 　Tischkowitz M, Brunet JS, Bgin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7(1): 134.
31. (9676): 1681-1692.

Previous Article
Secondary Acute Myeloid Leukemia M6 after Treatment of Non-Hodgkin’s Lymphoma: A Report of One Case
Next Article
CD4+ T细胞介导的免疫反应在面神经损伤修复中的作用

West China Medical Journal

三阴乳腺癌的内科治疗进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content